391 related articles for article (PubMed ID: 19797729)
1. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
[TBL] [Abstract][Full Text] [Related]
2. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
[TBL] [Abstract][Full Text] [Related]
4. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
[TBL] [Abstract][Full Text] [Related]
7. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP
Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255
[TBL] [Abstract][Full Text] [Related]
9. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
10. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.
Gelsi-Boyer V; Cervera N; Bertucci F; Brecqueville M; Finetti P; Murati A; Arnoulet C; Mozziconacci MJ; Mills KI; Cross NC; Vey N; Birnbaum D
Haematologica; 2013 Apr; 98(4):576-83. PubMed ID: 23065512
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
[No Abstract] [Full Text] [Related]
12. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
[TBL] [Abstract][Full Text] [Related]
13. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
[TBL] [Abstract][Full Text] [Related]
14. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.
Chapman J; Geyer JT; Khanlari M; Moul A; Casas C; Connor ST; Fan YS; Watts JM; Swords RT; Vega F; Orazi A
Mod Pathol; 2018 Mar; 31(3):429-441. PubMed ID: 29192651
[TBL] [Abstract][Full Text] [Related]
15. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
[TBL] [Abstract][Full Text] [Related]
16. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
18. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G
Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791
[TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]